| review article | Q7318358 |
| scholarly article | Q13442814 |
| P6179 | Dimensions Publication ID | 1030509893 |
| P356 | DOI | 10.1007/S11894-002-0036-9 |
| P698 | PubMed publication ID | 11825540 |
| P2093 | author name string | Paul Angulo | |
| P2860 | cites work | A multicenter, controlled trial of ursodiol for the treatment of primary biliary cirrhosis. UDCA-PBC Study Group | Q28243457 |
| Hepatocellular and biliary expression of HLA antigens in primary biliary cirrhosis before and after ursodeoxycholic acid therapy | Q28332915 | ||
| Stimulation of ATP secretion in the liver by therapeutic bile acids | Q28345188 | ||
| An NO derivative of ursodeoxycholic acid protects against Fas-mediated liver injury by inhibiting caspase activity | Q28354314 | ||
| Ursodeoxycholic acid may inhibit deoxycholic acid-induced apoptosis by modulating mitochondrial transmembrane potential and reactive oxygen species production | Q28379482 | ||
| Ursodiol use is associated with lower prevalence of colonic neoplasia in patients with ulcerative colitis and primary sclerosing cholangitis | Q31933357 | ||
| Ursodeoxycholic acid administration in patients with cholestasis of pregnancy: effects on primary bile acids in babies and mothers | Q32075349 | ||
| Review article: mechanisms of action and therapeutic applications of ursodeoxycholic acid in chronic liver diseases | Q33723536 | ||
| Randomised controlled trials of ursodeoxycholic-acid therapy for primary biliary cirrhosis: a meta-analysis | Q33745849 | ||
| Treatment of nonalcoholic fatty liver: present and emerging therapies | Q33941971 | ||
| Ursodeoxycholic acid 'mechanisms of action and clinical use in hepatobiliary disorders'. | Q34330984 | ||
| A novel role for ursodeoxycholic acid in inhibiting apoptosis by modulating mitochondrial membrane perturbation | Q37383640 | ||
| Pharmacology of ursodeoxycholic acid, an enterohepatic drug. | Q40571618 | ||
| The effect of ursodeoxycholic acid therapy on liver fibrosis progression in primary biliary cirrhosis | Q40737262 | ||
| Therapy of hepatitis C: other options | Q40882236 | ||
| Combined analysis of randomized controlled trials of ursodeoxycholic acid in primary biliary cirrhosis | Q40883127 | ||
| Ursodeoxycholate increases cytosolic calcium concentration and activates CI− currents in a biliary cell line | Q41302359 | ||
| Gallstone dissolution with ursodeoxycholic acid in patients with chronic active hepatitis and two years follow-up. A pilot study | Q41916901 | ||
| A two-year prospective study of the effect of ursodeoxycholic acid on urinary bile acid excretion and liver morphology in cystic fibrosis-associated liver disease | Q42545724 | ||
| High-dose ursodeoxycholic acid as a therapy for patients with primary sclerosing cholangitis | Q43618408 | ||
| Incomplete response to ursodeoxycholic acid in primary biliary cirrhosis: is a double dosage worthwhile? | Q43807982 | ||
| A prospective, randomized, double-blind trial evaluating the efficacy of ursodeoxycholic acid in prevention of liver transplant rejection | Q44742871 | ||
| Ursodeoxycholic acid in the treatment of cholestasis of pregnancy: a randomized, double-blind study controlled with placebo | Q47869512 | ||
| The Canadian Multicenter Double-blind Randomized Controlled Trial of ursodeoxycholic acid in primary biliary cirrhosis | Q49110706 | ||
| Cost-effectiveness of ursodeoxycholic acid therapy in primary biliary cirrhosis. | Q50636830 | ||
| A randomized, double-blind, placebo-controlled trial of ursodeoxycholic acid in primary biliary cirrhosis | Q51586165 | ||
| Kinetics of hepatic bile acid handling in cholestatic liver disease: effect of ursodeoxycholic acid. | Q51597193 | ||
| A randomized clinical trial of ursodeoxycholic acid as adjuvant treatment to prevent liver transplant rejection. | Q53963820 | ||
| Effect of cholestasis and bile acids on interferon-induced 2′, 5′-adenylate synthetase and NK cell activities | Q54176496 | ||
| Dissolution of cholesterol gallstones by long-term administration of ursodeoxycholic acid | Q67717951 | ||
| Hepatic expression of class I and class II major histocompatibility complex molecules in primary biliary cirrhosis: effect of ursodeoxycholic acid | Q68925952 | ||
| Is ursodeoxycholic acid an effective treatment for primary biliary cirrhosis? | Q69896715 | ||
| Treatment with ursodeoxycholic acid renders children with biliary atresia suitable for liver transplantation | Q69909459 | ||
| Ursodeoxycholic acid: a safe and effective agent for dissolving cholesterol gallstones | Q70260265 | ||
| Ursodeoxycholic acid or clofibrate in the treatment of non-alcohol-induced steatohepatitis: a pilot study | Q71173357 | ||
| Hypercholeresis induced by ursodeoxycholic acid and 7-ketolithocholic acid in the rat: possible role of bicarbonate transport | Q71211586 | ||
| Ursodeoxycholic acid corrects defective natural killer activity by inhibiting prostaglandin E2 production in primary biliary cirrhosis | Q71214957 | ||
| Ursodeoxycholic acid for treatment of cholestasis in children on long-term total parenteral nutrition: a pilot study | Q71466339 | ||
| Failure of ursodeoxycholic acid to prevent acute cellular rejection after liver transplantation | Q71586749 | ||
| Decreased anion exchanger 2 immunoreactivity in the liver of patients with primary biliary cirrhosis | Q71949350 | ||
| Ursodeoxycholic acid in the treatment of primary biliary cirrhosis | Q72401649 | ||
| Ursodiol for primary sclerosing cholangitis. Mayo Primary Sclerosing Cholangitis-Ursodeoxycholic Acid Study Group | Q73090826 | ||
| Ursodeoxycholic acid therapy in pediatric patients with progressive familial intrahepatic cholestasis | Q73107770 | ||
| Ursodeoxycholic acid as adjunctive therapy for problematic type 1 autoimmune hepatitis: a randomized placebo-controlled treatment trial | Q73208571 | ||
| Low-dose versus high-dose ursodeoxycholic acid in cystic fibrosis-related cholestatic liver disease. Results of a randomized study with 1-year follow-up | Q73317238 | ||
| The Nordic multicenter double-blind randomized controlled trial of prophylactic ursodeoxycholic acid in liver transplant patients | Q73445481 | ||
| Ursodeoxycholic acid for primary biliary cirrhosis | Q73497916 | ||
| Long-term effects of ursodeoxycholic acid in primary biliary cirrhosis: results of a double-blind controlled multicentric trial. UDCA-Cooperative Group from the Spanish Association for the Study of the Liver | Q73715566 | ||
| Long-term ursodeoxycholic acid delays histological progression in primary biliary cirrhosis | Q74529900 | ||
| Ursodiol prophylaxis against hepatic complications of allogeneic bone marrow transplantation. A randomized, double-blind, placebo-controlled trial | Q74644488 | ||
| Comparison of three doses of ursodeoxycholic acid in the treatment of primary biliary cirrhosis: a randomized trial | Q77872001 | ||
| Ursodeoxycholic acid inhibits eosinophil degranulation in patients with primary biliary cirrhosis | Q77933487 | ||
| Efficacy of ursodeoxycholic acid in Japanese patients with type 1 autoimmune hepatitis | Q93910045 | ||
| P433 | issue | 1 | |
| P304 | page(s) | 37-44 | |
| P577 | publication date | 2002-02-01 | |
| P1433 | published in | Current gastroenterology reports | Q26842032 |
| P1476 | title | Use of ursodeoxycholic acid in patients with liver disease | |
| P478 | volume | 4 |
| Q92969424 | A case of idiopathic GGT elevation with acute hepatitis A |
| Q34130429 | A pilot trial of high-dose ursodeoxycholic acid in nonalcoholic steatohepatitis |
| Q36393412 | Cow dung powder poisoning |
| Q35124679 | Current best treatment for non-alcoholic fatty liver disease |
| Q37847138 | Current management of primary sclerosing cholangitis in pediatric patients |
| Q35010921 | Effects of ursodeoxycholic acid and/or low-calorie diet on steatohepatitis in rats with obesity and hyperlipidemia |
| Q37141253 | Guidelines for the diagnosis and treatment of nonalcoholic fatty liver diseases |
| Q37294587 | Intrahepatic cholestasis of pregnancy-current achievements and unsolved problems |
| Q33867088 | Mechanisms inactivating the gene for E-cadherin in sporadic gastric carcinomas |
| Q45151761 | Meta-analysis: ursodeoxycholic acid for primary sclerosing cholangitis |
| Q36197335 | Molecular mechanisms of ursodeoxycholic acid toxicity & side effects: ursodeoxycholic acid freezes regeneration & induces hibernation mode. |
| Q38733145 | NCX 1000 Alone or in Combination with Vitamin E Reverses Experimental Nonalcoholic Steatohepatitis in the Rat Similarly to UDCA. |
| Q35543956 | Non-alcoholic fatty liver disease: The diagnosis and management |
| Q37345907 | Nonalcoholic fatty liver disease: from clinical recognition to treatment |
| Q33628158 | Pretreatment with ursodeoxycholic acid (UDCA) as a novel pharmacological intervention in hepatobiliary scintigraphy |
| Q45137237 | Role of ursodeoxycholic acid in pediatric cholestatic disease |
| Q35217035 | The combination of ezetimibe and ursodiol promotes fecal sterol excretion and reveals a G5G8-independent pathway for cholesterol elimination |
| Q55380468 | Treatment of nonalcoholic fatty liver disease. |
| Q34155978 | Ursodeoxycholic acid ameliorates fructose-induced metabolic syndrome in rats |
| Q37459208 | Ursodeoxycholic acid inhibits liver X receptor α-mediated hepatic lipogenesis via induction of the nuclear corepressor SMILE. |
| Q51373827 | Ursodeoxycholic acid treatment of hepatic steatosis: a (13)C NMR metabolic study. |
Search more.